In this episode of the Oncology Brothers podcast, we were joined by Dr. Erika Hamilton from the Sarah Cannon Research Institute to discuss key abstracts presented at ASCO 2024 in the field of breast cancer. The episode covered a range of topics including updates on hormone receptor positive breast cancer, the use of CDK4/6 inhibitors in metastatic settings, and the evolving landscape of HER2-targeted therapies.
- RxPONDER: AMH levels identifying premenopausal pts with HR+, HER2-, node+ to benefit from adj chemo
- postMONARCH: Abema/Fulv vs. Fulv for HR+, HER2- mBC post progession on prior CDK4/6i/ET
- INAVO120: inavo/Pbo+Palbo+Fulv in pts with PIK3CA-mut, HR+, HER2- mBC
- DESTINY-Breast06: T-DXd vs chemo in pts with HR+, HER2-low or ultralow in mBC with prior ET
- JBCRRG-M06/EMERALD: Trast + Pert + Eribulin or a Taxane as first-line chemo Rx for HER2+ mBC
Dr. Hamilton provided insights on the RxPonder study, highlighting the importance of AMH levels in determining the need for chemotherapy in postmenopausal patients. She also discussed the postMONARCH study, which examined the efficacy of adding abemaciclib after progression on CDK4/6 inhibitors in hormone receptor positive breast cancer.
The conversation then shifted to the INAVO120 trial, which focused on first-line treatment options for patients with PI3 alterations who relapsed quickly after adjuvant therapy. Dr. Hamilton emphasized the potential paradigm shift in treatment strategies for high-risk patients based on the trial results.
The discussion also touched on the evolving classification of HER2 status, particularly in light of the DESTINY-Breast06 study, which questioned the need to check HER2 status given the efficacy of trastuzumab deruxtecan in
Lastly, the Emerald trial was discussed, highlighting the comparison of eribulin with taxanes in HER2-positive metastatic breast cancer. Dr. Hamilton shared insights on the practical implications of the study and its potential impact on treatment decisions.
Overall, the episode provided valuable insights into the latest advancements in breast cancer treatment and the importance of biomarker testing in guiding personalized treatment strategies. Listeners were encouraged to stay tuned for more ASCO 2024 highlights across different cancer types.
